genetic research have identified many susceptibility genes or loci associated with common diseases, however, there is scarce information about the clinical utility of identified genetic factors on the treatment and prevention of common diseases. Moreover, the information concerning environmental or lifestyle factors that modify the genetic risk of common diseases is limited.
Although Biobank Japan project have developed genetic information of genome-wide genotyping data in 200,000 patients, there have been no report on the clinical information corresponding to these patients because this project was initially designed by focusing on the use of genetic research only. In 2009, Biobank Japan project launched a Clinical Data Analysis Working Group organized by Guest Editors and started the survival survey of approximately 150,000 patients from 2011. This survival survey was successfully accomplished with the strong cooperation of 12 medical institutions and MEXT, and resulted in the high follow-up rate (97.0%) with the mean follow-up period of 7.7 years. Moreover, Biobank Japan project collected various clinical information from medical records in 200,000 patients annually from the registration to fiscal 2012. Hence, Clinical Data Analysis Working Group started data cleansing of this huge clinical data from 2013 and constructed a large clinical database consisting of up to 10 year consecutive clinical information including disease status, laboratory examination, and drug information etc. Using this large clinical database, Clinical Data Analysis Working Group reported epidemiological aspects of Biobank Japan samples in this supplement. I hope the manuscripts published in this supplement will guide to the further understanding of Biobank Japan samples and promote further analysis toward the implementation of precision/personalized medicine.
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